TITLE

Drugs Used to Treat Spasticity

AUTHOR(S)
Kita, M.; Goodkin, D.E.
PUB. DATE
March 2000
SOURCE
Drugs;Mar2000, Vol. 59 Issue 3, p487
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Spasticity is a common and disabling symptom for many patients with upper motor neuron dysfunction. It results from interruption of inhibitory descending spinal motor pathways, and although the pathophysiology of spasticity is poorly understood, the final common pathway is overactivity of the alpha motor neuron. Therapy for spasticity is symptomatic with the aim of increasing functional capacity and relieving discomfort. Any approach to treatment should be multidisciplinary, including physical therapy, and possibly surgery, as well as pharmacotherapy. It is important that treatment be tailored to the individual patient, and that both patient and care giver have realistic expectations. Pharmacotherapy is generally initiated at low dosages and then gradually increased in an attempt to avoid adverse effects. Optimal therapy is the lowest effective dosage. Baclofen, diazepam, tizanidine and dantrolene are currently approved for use in patients with spasticity. In addition, clonidine (usually as combination therapy), gabapentin and botulinum toxin have shown efficacy, however, more studies are required to confirm their place in therapy. Intrathecal baclofen, via a surgically implanted pump and reservoir, may provide relief in patients with refractory severe spasticity.
ACCESSION #
9593089

 

Related Articles

  • Poster 260 Intrathecal Baclofen for Severe Spasticity in Patients With Upper Motor Neuron Disease. Bethoux, Francois A.; Hussain, Mariam; Stough, Darlene; Sutliff, Matthew // PM & R: Journal of Injury, Function & Rehabilitation;Sep2011 Supplement, Vol. 3 Issue 10S, pS261 

    No abstract available.

  • Predicting ALS Progression. Rubin, Michael // Neurology Alert;Sep2007, Vol. 26 Issue 1, p2 

    The diagnosis of amyotrophic lateral sclerosis (ALS) is devastating for patient and family alike. Nevertheless, the ability to predict which patients with lower motor neuron disease will progress to full blown ALS would be beneficial by enabling earlier enrollment into clinical trials, offering...

  • TDP-43 pathology in a case of hereditary spastic paraplegia with a NIPA1/SPG6 mutation. Martinez-Lage, Maria; Molina-Porcel, Laura; Falcone, Dana; McCluskey, Leo; Lee, Virginia; Deerlin, Vivianna; Trojanowski, John // Acta Neuropathologica;Aug2012, Vol. 124 Issue 2, p285 

    Mutations in NIPA1 (non-imprinted in Prader-Willi/Angelman syndrome) have been described as a cause of autosomal dominant hereditary spastic paraplegia (HSP) known as SPG6 (spastic paraplegia-6). We present the first neuropathological description of a patient with a NIPA1 mutation, and clinical...

  • Data condensed synthesis regarding kinesiotherapeutic procedures used in spasticity therapy. Moraru, E.; Onose, G. // Journal of Medicine & Life;Jul-Sep2014, Vol. 7 Issue 3, p317 

    Spasticity represents an important feature of the upper motoneuron syndrome (UMNS). The clinical signs, such as the abnormal movement models, the unwanted muscular co-contractions, the muscular and joint rigidity with a consecutive deformity can be signs of spasticity and, also of upper...

  • Approach to spasticity in General practice. Bavikatte, Ganesh; Gaber, Tarek // British Journal of Medical Practitioners;2009, Vol. 2 Issue 3, p29 

    Spasticity is a physiological consequence of an injury to the nervous system. It is a complex problem which can cause profound disability, alone or in combination with the other features of an upper motor neuron syndrome and can give rise to significant difficulties in the process of...

  • Motor Neuron Disease Presenting as Low Back Ache: A Case Report. Sharma, Vivek; Kaur, Harraman; Malhotra, L. K. // Physiotherapy & Occupational Therapy Journal;Jul-Sep2013, Vol. 6 Issue 3, p143 

    Motor neuron disease (MND) is a progressive neurodegenerative disorder, manifested by upper and lower motor neuron signs and symptoms. It is characterized by progressive weakness, atrophy, spasticity, dysarthria, dysphagia, and respiratory compromise, ultimately resulting in death. The initial...

  • Overcoming the barrier to ALS. Gaillard, P. J. // Laboratory News;May2013, Issue 5, p20 

    The article reports on the management of amyotrophic lateral sclerosis (ALS), a neurodegenerative condition for which there is currently no effective treatment. It states the significance of enhancing drug delivery to the brain of potential management of this disease. ALS is characterized by...

  • Amyotrophic Lateral Sclerosis As A Paraneoplastic Manifestation in the Neuroendocrine Tumor of Stomach: A Case Report. Mehrpour, Masoud; Mohebi, Nafiseh; Motamed, Mohammad Reza; Zamani, Farhad // Acta Medica Iranica;2013, Vol. 51 Issue 10, p724 

    Motor neuron diseases have been reported as a rare paraneoplastic syndrome (PNS) of a systemic neoplasm. We present a patient with amyotrophic lateral sclerosis (ALS) in association with neuroendocrine tumor (NET) of stomach, which is the first case of motor neuronopathy with underlying...

  • BOTULINO TOKSINO IR KINEZITERAPIJOS POVEIKIS 4-7 METŲ VAIKAMS, TURINTIEMS CEREBRINÄ® PARALYŽIŲ. Selvenytė, Edita // Special Education;2008, Issue 1, p169 

    Cerebral palsy, a range of non-progressive syndromes of posture and motor impairment, is a common cause of disability in childhood. Cerebral palsy results from a permanent static lesion of the cerebral motor cortex that occurs before, at, or within 2 years of birth. Injury to upper motor neurons...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics